The drug candidate – called vorasidenib – is a dual inhibitor of mutated IDH1 and IDH2, which is being developed for a hard-to-treat form of brain cancer called glioma. It was acquired by ...

Gliomas are the most common brain tumors, and many start off growing slowly as "low-grade" tumors before inevitably becoming ...

The results of this trial will have an immediate clinical impact. "Since the results of RTOG 9802 came out in 2014, patients ...

The artificial intelligence (AI) model FastGlioma can detect glioma infiltration during surgery, according to a study published online Nov. 13 in Nature. Akhil Kondepudi, from the University of ...

Adding rhIL‑7-hyFc to radiation and temozolomide may improve survival in patients with high-grade glioma who are 65 years of age and older.

An immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant in a Stanford ...

HOUSTON -- Progression-free survival (PFS) in IDH -mutant low-grade glioma remained twice as high in adults who received ...

DIPG, which stands for diffuse intrinsic pontine glioma, is considered a universally fatal disease. It can wreak its havoc quickly, and the five-year survival rate is below 1%. “These are ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

The combination of Novartis’ Finlee (dabrafenib) and Spexotras (trametinib) is now recommended by NICE for paediatric patients with relapsed/refractory BRAF V600E-positive glioma, within three ...